Skip to main content
. 2023 Jul 3;12(13):4463. doi: 10.3390/jcm12134463

Figure 1.

Figure 1

Flow chart of patients in this study. In cohort 1, liver-related death-free survival and HCC-free survival were evaluated in patients with AIH. In cohort 2, the efficacy of serum biomarkers for predicting long-term prognosis was evaluated in patients with AIH. AIH, autoimmune hepatitis; HCC, hepatocellular carcinoma.